Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LM-299 + Raludotatug deruxtecan |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LM-299 | LM 299|LM299 | PD-L1/PD-1 antibody 138 VEGF Antibody 17 | Limited information is currently available on LM-299, a putative bispecific antibody targeting PD-1 and VEGF (May 2025). | |
| Raludotatug deruxtecan | DS 6000a|DS-6000|DS6000a|DS-6000a|R-DXd|MK-5909 | Raludotatug deruxtecan (DS-6000a) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH6 linked to the cytotoxic DNA topoisomerase inhibitor DXd, which binds to CDH6 expressed on tumor cells and potentially induces tumor cell apoptosis and inhibits tumor growth (PMID: 38205802). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06843447 | Phase Ib/II | Bevacizumab-awwb + Pembrolizumab + Raludotatug deruxtecan Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab + Raludotatug deruxtecan LM-299 + Raludotatug deruxtecan Bevacizumab + Carboplatin + Gemcitabine Carboplatin + Raludotatug deruxtecan Paclitaxel + Raludotatug deruxtecan Bevacizumab + Raludotatug deruxtecan Bevacizumab + Paclitaxel + Raludotatug deruxtecan Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Pegylated liposomal doxorubicin Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Raludotatug deruxtecan | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Recruiting | USA | ISR | GBR | ESP | CAN | 0 |
CKB BOOST